Flt-3/Flk-2 Activators
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quizartinib, Free Base | 950769-58-1 | sc-396767 sc-396767A | 1 mg 5 mg | $68.00 $150.00 | ||
Quizartinib is a selective inhibitor of FLT3, specifically targeting the FLT3-ITD mutation. By inhibiting FLT3 kinase activity, quizartinib prevents the constitutive activation of downstream signaling pathways, including the MAPK and PI3K/AKT pathways. This inhibition can lead to the suppression of aberrant proliferation and survival signals, potentially normalizing FLT3/Flk-2 activity in leukemia cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets FLT3, among other kinases. By inhibiting FLT3, sorafenib disrupts the constitutive activation of downstream signaling pathways, such as MAPK and STAT5. This interference with aberrant signaling pathways may contribute to the normalization of FLT3/Flk-2 activity in leukemia cells, potentially suppressing the uncontrolled proliferation and survival signals associated with FLT3 mutations. | ||||||
Crenolanib | 670220-88-9 | sc-364470 sc-364470A | 5 mg 10 mg | $612.00 $1020.00 | ||
Crenolanib is a selective inhibitor of FLT3, designed to target both FLT3-ITD and FLT3-TKD mutations. Through the inhibition of FLT3 kinase activity, crenolanib disrupts aberrant downstream signaling pathways, including MAPK and PI3K/AKT. This disruption may lead to the attenuation of abnormal cellular responses driven by FLT3 mutations, potentially restoring more controlled FLT3/Flk-2 activity in leukemia cells. | ||||||
ABT-869 | 796967-16-3 | sc-359037 sc-359037A | 1 mg 5 mg | $126.00 $582.00 | ||
Linifanib is a multi-kinase inhibitor that targets FLT3, VEGFR, and PDGFR. By inhibiting FLT3, linifanib interferes with the constitutive activation of signaling pathways downstream of FLT3, such as MAPK and STAT5. This interference may contribute to the normalization of FLT3/Flk-2 activity in leukemia cells, potentially mitigating the uncontrolled proliferation and survival signals associated with FLT3 mutations. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $52.00 $114.00 | 10 | |
Midostaurin is a multi-kinase inhibitor with activity against FLT3, among other kinases. By inhibiting FLT3 kinase activity, midostaurin disrupts the constitutive activation of downstream signaling pathways, including MAPK and PI3K/AKT. This disruption may contribute to the normalization of FLT3/Flk-2 activity in leukemia cells, potentially suppressing the uncontrolled proliferation and survival signals associated with FLT3 mutations. | ||||||
KW 2449 | 1000669-72-6 | sc-364518 sc-364518A | 10 mg 50 mg | $180.00 $744.00 | ||
KW2449 is a multi-kinase inhibitor that targets FLT3 and other receptor tyrosine kinases. By inhibiting FLT3, KW2449 disrupts downstream signaling pathways, including MAPK and PI3K/AKT. This disruption may contribute to the normalization of FLT3/Flk-2 activity in leukemia cells, potentially mitigating the uncontrolled proliferation and survival signals associated with FLT3 mutations. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that can target FLT3 among various kinases. By inhibiting FLT3 kinase activity, staurosporine disrupts downstream signaling pathways, including MAPK and PI3K/AKT. This disruption may contribute to the normalization of FLT3/Flk-2 activity in leukemia cells, potentially suppressing the uncontrolled proliferation and survival signals associated with FLT3 mutations. | ||||||